Molecular Markers and Prostate Cancer Prognosis

Chin, Jonathan L; Reiter, Robert E.

doi:10.3816/cgc.2004.n.026

Cited by 21 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various clinical variables have been used, singly and in combination (nomograms, tables, etc. ), to predict, preoperatively, which patients are likely to fail definitive therapy (4). However, the predictive value of these variables has been thwarted by the vexing biological diversity of clinical prostate cancer.…”

mentioning

confidence: 99%

Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

Tahir¹,

Frolov²,

Hayes

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Up-regulation of caveolin-1 (cav-1) is associated with virulent prostate cancer, and serum cav-1levels are elevated in prostate cancer patients but not in benign prostatic hyperplasia. In this study, we evaluated the potential of high preoperative serum cav-1 levels to predict biochemical progression of prostate cancer. The value of the combined preoperative markers, prostate-specific antigen (PSA), biopsy Gleason score, and serum cav-1for predicting biochemical recurrence was also investigated. Experimental Design: Serum samples taken from 419 prostate cancer patients before radical prostatectomy were selected from our Specialized Programs of Research Excellence prostate cancer serum and tissue bank. Serum samples were obtained 0 to 180 days before surgery and all patients had complete data on age, sex, race, stage at enrollment, and follow-up for biochemical recurrence. Serum cav-1 levels were measured according to our previously reported ELISA protocol.Results: Cav-1levels were measured in the sera of 419 prostate cancer patients; the mean serum level was 4.52 ng/mL (median 1.01ng/mL). Patients with high serum cav-1levels had a 2.7-fold (P = 0.0493) greater risk of developing biochemical recurrence compared with those with low serum cav-1levels. Importantly, patients with serum PSA z10 ng/mL and elevated levels of serum cav-1had 2.44 times higher risk (P = 0.0256) of developing biochemical recurrence compared with patients with low levels of cav-1. In addition, high serum cav-1levels combined with increasing biopsy Gleason score predicted much shorter recurrence-free survival in the group of patients with PSA z 10 ng/mL (P = 0.0353). Cav-1was also able to distinguish between high-and low-risk patients with biopsy Gleason score of seven, after adjusting, for patients PSA levels (P = 0.0429). Conclusions: Overall, elevated preoperative levels of serum cav-1 predict decreased time to cancer recurrence. In the subset of patients with serum PSA of z10 ng/mL, the combination of serum cav-1and biopsy Gleason score has the capacity to predict time to biochemical recurrence.

show abstract

mentioning

confidence: 99%

Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

Tahir¹,

Frolov²,

Hayes

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Serum PSA levels correlate only marginally with cancer volume as, on a per cell basis, higher expression is noted in benign prostate cells than cancerous cells 27. Many studies have explored a potential utility for tissue‐based gene or protein markers to add to prognostic information obtained from standard histology 28–32. In this study, we show that β2M expression in primary prostate cancer specimens is associated with features linked to clinically aggressive disease including high Gleason grade and the presence of perineural invasion.…”

Section: Discussionmentioning

confidence: 79%

Beta‐2‐microglobulin expression correlates with high‐grade prostate cancer and specific defects in androgen signaling

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A recent study showed that cases positive for the antibodies S0456, EP1972-1, S0725M, and S5073, which are directed against the protein products of the genes Hey2 , STMN1 , CYP4Z1 , and CDH1 , had poorer prognosis than did those that were negative for these antibodies [11,12]. Although the study did not deal with hypoechoic lesions on TRUS, the authors speculated that such molecular markers may be detected in prostate cancer with hypoechoic lesions.…”

Section: Discussionmentioning

confidence: 99%

Does the Presence of Hypoechoic Lesions on Transrectal Ultrasound Suggest a Poor Prognosis for Patients With Localized Prostate Cancer?

et al. 2013

View full text Add to dashboard Cite

PurposeThe purpose of this study was to investigate the value of hypoechoic lesions on transrectal ultrasound (TRUS) as a prognostic factor for patients with localized prostate cancer.Materials and MethodsThe patients consisted of 71 patients with pT2N0M0 disease following radical prostatectomy between 2002 and 2008. The group with hypoechoic lesions was labeled group 1, whereas the group without hypoechoic lesions was labeled group 2. The presence of hypoechoic lesions on preoperative TRUS was analyzed as a prognostic factor along with several parameters, including preoperative factors and pathologic factors. The biochemical progression-free survival (BPFS) rate was compared between the two groups according to the presence of hypoechoic lesions on TRUS.ResultsA total of 35 patients had hypoechoic lesions on TRUS, whereas 36 had no hypoechoic lesions. Preoperative baseline characteristics were not significantly different between the two groups. In the univariate analysis, BPFS showed significant differences according to the presence of hypoechoic lesions on TRUS and the preoperative prostate-specific antigen level. The BPFS rates over the first 24 months were 97.0% in group 1 and 97.1% in group 2; however, the difference in the BPFS rate over 48 months significantly widened to 75.3% compared with 91.7%, respectively. Despite this finding, no significant independent prognostic factor for BPFS was found on multivariate analysis in this patient cohort.ConclusionsThe presence of hypoechoic lesions on TRUS may suggest worse prognostic characteristics in pT2 prostate cancer. Further studies involving larger subject populations are needed to corroborate the significance of the presence of hypoechoic lesions as a prognostic factor.

show abstract

Molecular Markers and Prostate Cancer Prognosis

Cited by 21 publications

References 59 publications

Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

Beta‐2‐microglobulin expression correlates with high‐grade prostate cancer and specific defects in androgen signaling

Does the Presence of Hypoechoic Lesions on Transrectal Ultrasound Suggest a Poor Prognosis for Patients With Localized Prostate Cancer?

Contact Info

Product

Resources

About